A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)
ABSTRACTThere is an ongoing burden of pneumococcal disease in children despite the use of pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite, descriptive study was designed to evaluate the safety and immunogenicity of a 3 + 1 regimen of V114 (VAXNEUVANCE™), a 15-...
Saved in:
Main Authors: | Alvino Maestri (Author), Su Eun Park (Author), Fiona Fernandes (Author), Zhongyi "Lucy" Li (Author), Yae-Jean Kim (Author), Yun-Kyung Kim (Author), Jin Lee (Author), Ji Young Park (Author), Dong Hyun Kim (Author), GyongSeon Yang (Author), Hyunjung Lim (Author), Jin Oh Kim (Author), Robert Lupinacci (Author), Tina M. Sterling (Author), Marissa Wilck (Author), Alejandra Esteves-Jaramillo (Author), Natalie Banniettis (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
by: Randall Severance, et al.
Published: (2022) -
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
by: Laura L. Hammitt, et al.
Published: (2023) -
Warlord of Kor
by: Carr, Terry, 1937-1987 -
The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
by: Yaru Shi, et al.
Published: (2023) -
Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
by: Jin-Woo Park, et al.
Published: (2021)